Trial of Roxithromycin in Subjects with Asthma and Serological Evidence of Infection withChlamydia pneumoniae
| Autor: | Raffaele Scicchitano, Peter N. Black, Graham Mills, Luigi Allegra, Abraham R. Rubinfeld, Peter R. Mullins, B. E M Denise David, Francesco Blasi, Richard E. Ruffin, Christine Jenkins, Bruce C. Cooper, Josette Dangain |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Time Factors Population Peak Expiratory Flow Rate Critical Care and Intensive Care Medicine medicine.disease_cause Placebo Severity of Illness Index Gastroenterology Double-Blind Method Forced Expiratory Volume Internal medicine Pneumonia Bacterial medicine Humans education Chlamydophila Infections Morning Antibacterial agent Asthma Roxithromycin education.field_of_study Chlamydia business.industry Chlamydophila pneumoniae Middle Aged medicine.disease Antibodies Bacterial Anti-Bacterial Agents respiratory tract diseases Treatment Outcome Immunoglobulin G Chronic Disease Immunology Female business Follow-Up Studies medicine.drug |
| Zdroj: | American Journal of Respiratory and Critical Care Medicine. 164:536-541 |
| ISSN: | 1535-4970 1073-449X |
| DOI: | 10.1164/ajrccm.164.4.2011040 |
| Popis: | An association has been reported between chronic infection with Chlamydia pneumoniae and the severity of asthma, and uncontrolled observations have suggested that treatment with antibiotics active against C. pneumoniae leads to an improvement in asthma control. We studied the effect of roxithromycin in subjects with asthma and immunoglobulin G (IgG) antibodies to C. pneumoniae > or = 1:64 and/or IgA antibodies > or = 1:16. A total of 232 subjects, from Australia, New Zealand, Italy, or Argentina, were randomized to 6 wk of treatment with roxithromycin 150 mg twice a day or placebo. At the end of 6 wk, the increase from baseline in evening peak expiratory flow (PEF) was 15 L/min with roxithromycin and 3 L/min with placebo (p = 0.02). With morning PEF, the increase was 14 L/min with roxithromycin and 8 L/min with placebo (NS). In the Australasian population, the increase in morning PEF was 18 L/min and 4 L/min, respectively (p = 0.04). At 3 mo and 6 mo after the end of treatment, differences between the two groups were smaller and not significant. Six weeks of treatment with roxithromycin led to improvements in asthma control but the benefit was not sustained. Further studies are necessary to determine whether the lack of sustained benefit is due to failure to eradicate C. pneumoniae. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|